Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2021 | Novel pharmacological approaches in Tourette’s syndrome

Tamara Pringsheim, MD, FAAN, University of Calgary, Calgary, AB, Canada, discusses novel pharmacological approaches for Tourette’s syndrome under investigation in clinical trials. VMAT2 inhibitors, deutetrabenazine and valbenazine, have been of substantial interest for the treatment of moderate to severe Tourette’s, but both failed to meet their primary endpoints of change in total tic score in recent major clinical trials. Other agents under investigation include ecopipam, an investigational first-in-class D1 antagonist, valproic acid, taurine and vitamin D. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.